Point72 Asset Management
ALXO icon

Point72 Asset Management’s ALX Oncology ALXO Stock Holding History

Point72 Asset Management’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-41,095
Closed -$82.4K – 3959
2026
Q1 		$82.4K Buy
41,095
+20,878
+103% +$39.8K ﹤0.01% 3630
2025
Q4 		$22.8K Buy
+20,217
New +$30.6K ﹤0.01% 3829
2024
Q3 		– Sell
-304,100
Closed -$1.83M – 1954
2024
Q2 		$1.83M Buy
+304,100
New +$3.74M ﹤0.01% 1119
2024
Q1 		– Sell
-913,700
Closed -$13.6M – 2142
2023
Q4 		$13.6M Buy
+913,700
New +$8.67M 0.03% 579
2023
Q2 		– Sell
-13,556
Closed -$61.3K – 2135
2023
Q1 		$61.3K Sell
13,556
-71,444
-84% -$541K ﹤0.01% 1747
2022
Q4 		$958K Sell
85,000
-297,500
-78% -$3.34M ﹤0.01% 1055
2022
Q3 		$3.66M Buy
+382,500
New +$4.46M 0.01% 809

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Point72 Asset Management's ALXO Position: Q2 2026 in Review

Point72 Asset Management sold out of ALX Oncology (ALXO) in Q2 2026, closing a stake of 41,095 shares — an estimated $82.4K sold.

Point72 Asset Management first reported a position in ALXO in Q3 2022 and held it in 7 quarters. The position peaked at $13.6M in Q4 2023. 94 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • Point72 Asset Management reported no remaining ALX Oncology position as of Q2 2026 after selling out during the quarter.
  • Point72 Asset Management sold 41,095 ALX Oncology shares in Q2 2026, an estimated $82.4K.
  • Point72 Asset Management first reported a position in ALX Oncology in Q3 2022 and held it in 7 quarters.
  • Point72 Asset Management's ALX Oncology position peaked at $13.6M in Q4 2023.
  • 94 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.